This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

-Type Endorphins and Schizophrenia

Wim M. A. Verhoeven, MD
Department of Psychiatry

Jan M. van Ree, MD; David de Wied, MD
Rudolf Magnus Institute for Pharmacology

Herman M. Van Praag, MD
Department of Psychiatry State University Nicolaas Beetsstraat 24 Utrecht, the Netherlands

Arch Gen Psychiatry. 1981;38(10):1182.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In reference to the article "Des-Tyrosine--Endorphin [DTE] Administration in Chronic Schizophrenics: A Preliminary Report" by Tamminga et al (Archives 1981;38:167-168), we agree with the conclusion of the authors that DTE does not have an antipsychotic activity in chronic (residual) schizophrenics. However, we found an antipsychotic action in more than 50% of our patients, which may be related to the type of schizophrenic illness and the history of our patients.

Based on animal experiments, de Wied et al¹ have postulated that DTE or a closely related neuropeptide may be an endogenous entity with antipsychotic activity and with a profile more specific than the currently used neuroleptic drugs. The results of our first two clinical studies with DTE in 13 patients with chronic relapsing schizophrenia and schizoaffective psychoses have been published in this journal.² Since that time, we have performed a third clinical trial including ten schizophrenic . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?